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Abstract
The intestinal microbiota is composed of hundreds of species of bacteria, fungi and protozoa and is critical for numerous
biological processes, such as nutrient acquisition, vitamin production, and colonization resistance against bacterial
pathogens. We studied the role of the intestinal microbiota on host resistance to Salmonella enterica serovar Typhimurium-
induced colitis. Using multiple antibiotic treatments in 129S1/SvImJ mice, we showed that disruption of the intestinal
microbiota alters host susceptibility to infection. Although all antibiotic treatments caused similar increases in pathogen
colonization, the development of enterocolitis was seen only when streptomycin or vancomycin was used; no significant
pathology was observed with the use of metronidazole. Interestingly, metronidazole-treated and infected C57BL/6 mice
developed severe pathology. We hypothesized that the intestinal microbiota confers resistance to infectious colitis without
affecting the ability of S. Typhimurium to colonize the intestine. Indeed, different antibiotic treatments caused distinct shifts
in the intestinal microbiota prior to infection. Through fluorescence in situ hybridization, terminal restriction fragment
length polymorphism, and real-time PCR, we showed that there is a strong correlation between the intestinal microbiota
composition before infection and susceptibility to Salmonella-induced colitis. Members of the Bacteroidetes phylum were
present at significantly higher levels in mice resistant to colitis. Further analysis revealed that Porphyromonadaceae levels
were also increased in these mice. Conversely, there was a positive correlation between the abundance of Lactobacillus sp.
and predisposition to colitis. Our data suggests that different members of the microbiota might be associated with S.
Typhimurium colonization and colitis. Dissecting the mechanisms involved in resistance to infection and inflammation will
be critical for the development of therapeutic and preventative measures against enteric pathogens.
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Introduction
The mammalian intestinal microbiota is a highly complex
community of microorganisms that live in close association with its
host. These microbes are important in numerous biological
processes and are essential for health. The phyla Firmicutes and
Bacteroidetes (BAC) comprise 90% of the intestinal microbiota,
whereas members of the Proteobacteria, Actinobacteria, Verru-
comicrobia and Cyanobacteria are present in low amounts [1].
The importance of the intestinal microbiota in human health is
increasingly acknowledged and a surge in the number of research
papers on the subject have been published in recent years.
Imbalances of the intestinal microbiota composition have been
linked to several diseases such as diabetes, inflammatory bowel
disease, colorectal cancer and atopic diseases [2,3,4,5].
Salmonella enterica serovar Typhimurium are Gram-negative,
facultative intracellular pathogens that cause a wide range of
human illnesses, from typhoid fever to gastroenteritis. In mice, S.
Typhimurium normally causes a disease that resembles systemic
typhoid fever. However, streptomycin treatment prior to S.
Typhimurium infection in mice leads to a disease similar to
salmonellosis in humans. Salmonellosis is marked by increased S.
Typhimurium colonization of the intestines and a strong
inflammatory response leading to colitis [6]. Recent work in our
lab described that treatments with low doses of streptomycin, a
broad-spectrum antibiotic, and vancomycin, an antibiotic target-
ing Gram-positive bacteria, altered the intestinal microbiota
composition of C57BL/6 mice and increased susceptibility to S.
Typhimurium infection and intestinal pathology, without chang-
ing overall numbers of intestinal microbiota [7].
In this study, we used several antibiotics to modify the intestinal
microbiota composition of 129S1/SvImJ mice, which are more
resistant to S. Typhimurium infection than C57BL/6 mice. We
showed that there is a strong correlation between distinct subsets of
the intestinal microbiota and protection against S. Typhimurium
colonization and associated colitis in this model. While treatments
with streptomycin and vancomycin increased both S. Typhimur-
ium colonization and intestinal inflammation, we found that
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Typhimurium without inducing colitis. However, metronidazole
treatment in C57BL/6 mice increased both colonization and
colitis, similar to the effects of streptomycin treatment in both
mouse strains. Differences in the intestinal microbiota composition
of these murine strains following metronidazole treatment and
similarities between streptomycin-treated 129S1/SvImJ and
metronidazole-treated C57BL/6 mice suggest that specific mem-
bers of the microbiota are associated with the development of
colitis. A better understanding of the role of specific members of
the microbiota in resistance to infection will help facilitate the
development of mechanisms to manipulate the intestinal micro-
biota for human benefit.
Results
Streptomycin, vancomycin and metronidazole
treatments increase intestinal colonization by S.
Typhimurium
In order to study the impact of antibiotic treatment on host
susceptibility to infection, we treated 129S1/SvImJ mice with
antibiotics in their drinking water before oral infection with S.
Typhimurium. Four days post-infection, mice were sacrificed and
samples from caecum, spleen and feces were analyzed. S.
Typhimurium caecal colonization was increased over ten-fold in
streptomycin-, vancomycin- and metronidazole-treated mice
compared to control-infected mice (Figure 1A). S. Typhimurium
counts were similar between mice treated with each of the different
antibiotics. Colonization levels in feces were comparable to the
counts obtained in caecal samples (Figure 1B). At the systemic level
(spleen), S. Typhimurium counts did not significantly change after
antibiotic treatment compared to the infected control mice (data
not shown).
Metronidazole treatment does not increase intestinal
pathology of Salmonella-infected 129S1/SvImJ mice
After S. Typhimurium infection, we observed that the intestines
of infected-only and metronidazole-treated infected mice had a
similar appearance, suggesting that treatment with this antibiotic
did not increase inflammation following infection. However, the
intestines of streptomycin- and vancomycin-treated mice appeared
shorter and lacked fecal matter, classical macroscopic signs of S.
Typhimurium-induced colitis (data not shown). In agreement with
our macroscopic observations, histological evaluation of haema-
toxilin-eosin stained caecal tissues from metronidazole-treated and
infected mice showed limited signs of inflammation (Figure 1C).
On the other hand, tissues from streptomycin- and vancomycin-
treated infected mice displayed markers of significant inflamma-
tion, with severe edema of the submucosa, necrotic cells and
neutrophils in the lumen and widespread presence of polymor-
phonuclear leukocytes (PMNs) in the epithelium. The degree of
tissue inflammation was further analyzed through pathological
scoring of caecal samples (Figure 1D). Pathology scores were
significantly different between metronidazole-treated infected mice
and streptomycin and vancomycin-treated infected mice, with the
latter two showing significantly stronger intestinal pathology.
These results indicate that even though S. Typhimurium
colonization levels were similar after each antibiotic treatment,
the intestinal pathology observed was strikingly different. Unlike
streptomycin and vancomycin, metronidazole pre-treatment does
not exacerbate S. Typhimurium-induced colitis. In order to gain
insights into the inflammation invoked by S. Typhimurium
infection after antibiotic pre-treatment, caecal cytokine levels of
129S1/SvImJ were analyzed by ELISAs (Figure 1E, 1F and 1G).
Metronidazole treatment prior to S. Typhimurium infection in
129S1/SvImJ mice did not significantly change IL6, IL8 or IFNc
production. However, streptomycin-treated and infected 129S1/
SvImJ mice showed increased levels of the cytokines tested. These
data are in agreement with the severe caecal pathology observed in
these mice, as these cytokines are involved in pro-inflammatory
responses.
Metronidazole treatment increases intestinal pathology
in Salmonella-infected C57BL/6 mice
In order to further characterize the phenotype seen with
metronidazole treatment, we investigated the effects of this
antibiotic in C57BL/6 mice prior to infection and compared the
results with those seen with 129S1/SvImJ mice. Consistent with
what was observed with 129S1/SvImJ mice, metronidazole
treatment of C57BL/6 animals significantly increased S. Typhi-
murium colonization of caecum and feces by over 10-fold
(Figure 2A and 2B). However, contrary to our observations of
metronidazole-treated 129S1/SvImJ, treatment of C57BL/6 mice
with this antibiotic significantly increased intestinal pathology
(Figure 2C and 2D). Cytokine levels in the ceacum of C57BL/6
mice were also analyzed (Fig 2E, 2F and 2G). Metronidazole-
treated and infected mice showed increased levels of IL6, IL8 and
IFNc compared to control mice, in agreement with the pathology
observed in these mice. Altogether these data indicate that the
same antibiotic can have opposite effects on different strains of
mice, presumably due to differences in microbiota and/or host
genetic background.
The difference in susceptibility to colitis displayed by
metronidazole-treated C57BL/6 and 129S1/SvImJ mice is
not due to Nramp1
One of the major differences between 129S1/SvImJ and
C57BL/6 mice is their Nramp1 (Natural resistance-associated
macrophage protein 1, also called Slc11a1) status, which
represents a critical host defense mechanism against S. Typhimur-
ium [8]. C57BL/6 mice are Nramp1 2/2 and, therefore, highly
susceptible to S. Typhimurium, succumbing to the disease within 5
days of infection. 129S1/SvImJ mice are Nramp1 +/+ and, as
such, are more resistant to and generally able to control the
infection. Therefore, we investigated whether the difference in
susceptibility to colitis between metronidazole-treated C57BL/6
and 129S1/SvImJ mice was due to their Nramp1 status. To do so,
both 129S1/SvImJ Nramp1 2/2 and +/+ mice were treated with
metronidazole prior to infection. Our results showed that
metronidazole treatment increased S. Typhimurium colonization
without increasing caecal inflammation in both Nramp1 2/2 and
+/+ mice (Figure S1). Therefore, the differences between
metronidazole treated 129S1/SvImJ and C57BL/6 mice are not
a result of differences in their Nramp1 status.
The susceptibility to colitis caused by antibiotic
treatment correlates with differences in the composition
of the intestinal microbiota
Initially, we investigated if bacterial abundance was affected by
the antibiotic treatments through SYBR green staining of fecal
samples. Total intestinal bacterial numbers did not significantly
change after any of the antibiotic treatments (Figure 3A),
suggesting that the changes observed are not simply due to a
decrease in total commensal numbers. We also analyzed the total
number of viable bacteria in fecal samples under aerobic and
anaerobic conditions. No significant changes were observed when
the total number of colonies grown under both conditions was
Microbiota Role in Salmonella-Induced Colitis
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number of colonies grown under aerobiosis in streptomycin-
treated 129S1/SvImJ mice (Figure S2). Terminal-restriction
fragment length polymorphism (TRFLP) was used to assess the
bacterial 16S rRNA composition of the feces of antibiotic-treated
uninfected mice. The use of fecal samples allowed us to collect
Figure 1. Different antibiotic treatments lead to different degrees of intestinal pathology in 129S1/SvImJ mice. A. S. Typhimurium
levels in caeca of 129S1/SvImJ mice after 4 days of infection with or without antibiotic treatment. B. S. Typhimurium levels in feces of 129S1/SvImJ
mice after 4 days of infection with or without antibiotic treatment. C. H&E staining of caeca of 129S1/SvImJ mice. (a). infected 129S1/SvImJ mice; (b).
metronidazole-treated and infected 129S1/SvImJ mice; (c). streptomycin-treated and infected 129S1/SvImJ mice; (d). vancomycin-treated and
infected 129S1/SvImJ mice. D. Pathology scores of caeca of 129S1/SvImJ mice after 4 days of infection with or without antibiotic treatment. E. Levels
of IL6 in caecal samples measured by ELISA. F. Levels of IL8 in caecal samples measured by ELISA. G. Levels of IFNc in caecal samples measured by
ELISA. Met: metronidazole (750 mg/L), Strep: streptomycin (450 mg/L) and Vanco: vancomycin (50 mg/L). Black bars represent pathology scores of
the intestinal lumen, white bars represent scores of the surface epithelia, dark grey bars represent scores of the mucosa and light grey bars represent
scores of the submucosa of the tissue. ns: not significant; *: p,0.05; **: p,0.01; ***: p#0.001. Experiments were performed three times with at least 4
mice in each group.
doi:10.1371/journal.pone.0020338.g001
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20338Figure 2. Metronidazole treatment prior to S. Typhimurium infection induces colitis in C57BL/6 mice. A. S. Typhimurium levels in caeca of
C57BL/6 mice after 4 days of infection with or without antibiotic treatment. B. S. Typhimurium levels in feces of C57BL/6 mice after 4 days of infection
with or without antibiotic treatment. C. H&E staining of caeca of C57BL/6 mice. (a). infected C57BL/6 mice; (b). metronidazole-treated and infected
C57BL/6 mice. D. Pathology scores of caeca of C57BL/6 mice after 4 days of infection with or without metronidazole treatment. E. Levels of IL6 in
caecal samples measured by ELISA. F. Levels of IL8 in caecal samples measured by ELISA. G. Levels of IFNc in caecal samples measured by ELISA. Met:
metronidazole (750 mg/L). Black bars represent pathology scores of the intestinal lumen, white bars represent scores of the surface epithelia, dark
grey bars represent scores of the mucosa and light grey bars represent scores of the submucosa of the tissue. *: p,0.05; **: p,0.01. Experiments
were performed three times with at least 4 mice in each group.
doi:10.1371/journal.pone.0020338.g002
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treatment without having to euthanize the animal. However, to
ensure that the results obtained with these samples were
representative of what occurred in the caecum, caecal microbiota
was also analyzed by TRFLP. No significant differences between
the fecal and caecal samples of mice from the same treatment were
observed (data not shown). The composition of each fecal sample
was plotted using non-metric multidimensional scaling (NMS)
ordination based on Sorensen distance measure to assess overall
changes in microbial community composition between treatment
groups [9]. Both metronidazole and streptomycin treatment in
129S1/SvImJ mice resulted in changes in microbial composition
(p,0.05, p,0.005, respectively) (Figure 3B and 3C). However,
streptomycin and metronidazole had distinct effects on the fecal
Figure 3. Different antibiotics have distinct effects on the composition of the intestinal microbiota. A. Total bacterial counts of fecal
samples of 129S1/SvImJ and C57BL/6 uninfected mice before and after antibiotic treatments, as determined by SYBR Green staining. B. Non-metrical
multidimentional scaling (NMS) ordination of Terminal restriction fragment length polymorphism (TRFLP) data of 129S1/SvImJ uninfected mice
before and after streptomycin or metronidazole treatment. Black triangles: naı ¨ve 129S1/SvImJ; green circles: metronidazole-treated 129S1/SvImJ; blue
squares: streptomycin-treated 129S1/SvImJ. C. Dendrogram of TRFLP data of 129S1/SvImJ mice before and after streptomycin or metronidazole
treatment. D. NMS ordination of TRFLP data of 129S1/SvImJ and C57BL/6 mice before and after metronidazole treatment. Black triangles: naı ¨ve
129S1/SvImJ; green circles: naı ¨ve C57BL/6; blue squares: metronidazole-treated 129S1/SvImJ; pink inverted triangles: metronidazole-treated C57BL/6.
E. Dendrogram of TRFLP data of 129S1/SvImJ and C57BL/6 mice before and after metronidazole treatment F. Microbial diversity in feces (Simpson’s
diversity index) before and after the antibiotic treatments. Met: metronidazole (750 mg/ L) and Strep: streptomycin (450 mg/ L). ns: not significant;
*: p,0.05; **: p,0.01; ***: p#0.001. Experiments were performed three times with at least 4 mice in each group.
doi:10.1371/journal.pone.0020338.g003
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microbiota that were positively and negatively correlated with
caecal pathology upon infection, respectively. The effect of
metronidazole treatment on the fecal microbiota of C57BL/6
mice was also compared to metronidazole-treated 129S1/SvlmJ
mice (Figure 3D and 3E). Despite the fact that the fecal microbiota
of the two mouse strains was relatively similar before antibiotic
treatment, metronidazole had a more marked effect on the
microbiota of C57BL/6 mice (p,0.005). Again, these changes
correlate well with the pathology observed after S. Typhimurium
infection, as streptomycin-treated 129S1/SvImJ and metronida-
zole-treated C57BL/6 mice exhibited stronger colitis compared to
metronidazole-treated 129S1/SvImJ mice. The microbial diversi-
ty, as assessed by Simpson’s index of diversity [10], indicate that
streptomycin treatment decreased diversity (p,0.05) in 129S1/
SvImJ mice, whereas metronidazole did not (Figure 3F). Interest-
ingly, metronidazole treatment of C57BL/6 mice did not
significantly alter the microbial diversity. Although this may seem
contradictory to our hypothesis that these parameters of
microbiota structure are responsible for susceptibility to colitis, it
is important to note that the diversity of C57BL/6 mice was much
lower than that observed in 129S1/SvImJ mice. It is possible that
this is an important determinant that may be predisposing
C57BL/6 mice to antibiotic-induced colitis.
Specific subsets of the intestinal microbiota can be
correlated with protection against colitis
By comparing the abundance of individual terminal restriction
fragment (TRF) lengths in protective versus non-protective
conditions it was possible to identify a small subset of TRFs that
were negatively and positively correlated with susceptibility to
colitis. Clone libraries of 16S rRNA genes were generated and
screened with restriction digestion to allow for phylogenetic
assignment of TRFs of interest. TRFs in the range of 83 to 87 bp
remained abundant after metronidazole treatment of 129S1/
SvImJ mice, but were significantly decreased in colitis-susceptible
mice, thus representing potentially protective organisms
(Figure 4A). Clones corresponding to these TRFs were all
classified within the family Porphyromonadaceae from the
Bacteroidetes phylum. Conversely, TRF188, identified as Lactoba-
cillus, was present at increased levels in streptomycin-treated
129S1/SvImJ and metronidazole-treated C57BL/6, but was not
detectable after metronidazole treatment of 129S1/SvImJ, and
was thus positively correlated with colitis susceptibility (Figure 4C).
We also found that TRF154 was present at significantly higher
levels in metronizadole-treated 129S1/SvImJ, but was unaffected
by other treatments (Figure 4B). Clones corresponding to this TRF
were classified within the family Lachnospiraceae. It is important
to note that an attempt to grow viable bacteria from the fecal
microbiota of the different groups in selective media showed no
correlation with the phenotypes observed in mice (data not
shown). This highlights the importance of DNA-based methodol-
ogies to thoroughly analyze the composition of the intestinal
microbiota.
Fluorescent in situ hybridization (FISH) was also performed to
further analyze the microbial composition of the intestinal
microbiota at the phylum level. For this purpose, we used specific
probes to calculate the percentages of Bacteroidetes (BAC),
Gammaproteobacteria (GAM) and Firmicutes and others (FIM)
in the intestinal microbiota. Consistent with the TRFLP data,
metronidazole treatment caused an increase in the BAC numbers
in 129S1/SvImJ mice (Figure 5) whereas a depletion of this
microbial group was seen in streptomycin-treated 129S1/SvImJ
and metronidazole-treated C57BL/6 mice. Therefore, BAC
abundance could correlate with resistance to colitis. On the other
hand, increased GAM numbers were observed in colitis-suscep-
tible mice prior to infection and seemed to correlate with increased
susceptibility to colitis.
Real-time PCR was used to confirm the results of TRFLP and
clone-library data, and to further characterize the abundance of
specific bacterial subsets that were below detection levels of
community profiling techniques. Because of the differences in the
Bacteroidetes numbers between the groups predisposed or
resistant to colitis, we investigated the levels of Mouse Intestinal
Bacteria (MIB) [11], a subset of Porphyromonadaceae, in these
mice. We also confirmed the results obtained by TRFLP, which
showed a prevalence of TRF188, identified as Lactobacillus sp., in
samples of mice predisposed to colitis. We observed that MIB
Figure 4. Specific members of the microbiota are involved in
predisposition to colitis. The contribution of individual peaks to the
total peak intensity of each sample was determined through TRFLP
analyses. A. Porphyromonadaceae (TFR 83–87). B. Lachnospiraceae (TRF
154). C. Lactobacillus sp. (TRF 187–188). ns: not significant; *: p,0.05;
**: p,0.01; ***: p#0.001. Experiments were performed three times with
at least 4 mice in each group.
doi:10.1371/journal.pone.0020338.g004
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129S1/SvImJ or metronidazole treatment of C57BL/6 mice, both
models that are predisposed to colitis. In contrast, MIB levels were
significantly increased after metronidazole treatment of 129S1/
SvImJ (Figure 6A). The opposite was seen when we analyzed
Lactobacillus numbers, which increased after streptomycin (colitis-
inducing) but not metronidazole (colitis non-inducing) treatment of
129S1/SvImJ (Figure 6B).
Because of the recent data on metronidazole treatment
increasing Bifidobacteria presence in the colon of rats [12], the
presence of Bifidobacteria was also determined in our models.
Bifidobacteria were below detection levels in 129S1/SvImJ mice, but
significantly increased after metronidazole treatment of C57BL/6
(data not shown). Additionally, segmented filamentous bacteria
(SFB) have also been shown to be an important component of the
intestinal microbiota, increasing resistance to the mouse pathogen
Citrobacter rodentium [13,14]. In our models, the presence of SFB
could not be detected in any of the samples analyzed (data not
shown), suggesting that these bacteria are not involved in the
development of colitis described here.
Discussion
Changes in the intestinal microbiota have been described as
important players in a vast number of both intestinal and extra-
intestinal diseases [15,16]. It has been shown that the composition
of the intestinal microbiota protects mice from S. Typhimurium
colonization in the gut [7]. In the present study, we describe that
the inflammatory process elicited during S. Typhimurium-induced
colitis is not due only to high levels of S. Typhimurium
encountered in the intestine after antibiotic treatment. Although
129S1/SvImJ mice treated with metronidazole prior to infection
had high levels of S. Typhimurium intestinal colonization, they did
not develop severe caecal pathology and did not show increased
levels of pro-inflammatory cytokines. On the other hand, mice
treated with streptomycin had high levels of S. Typhimurium as
well as marked signs of infectious colitis. We also showed that
metronidazole induces distinct caecal pathologies and inflamma-
tory responses in 129S1/SvImJ and C57BL/6 mice, which
coincided with differences in microbiota populations. This
indicates that differences in host microbiota might explain the
differences in the outcome of infection observed in our study. The
results obtained herein reflect the effect of the specific antibiotic
treatments described. Different antibiotic doses and different
treatment regimens may have had different outcomes in the
intestinal pathologies and host responses observed. Metronidazole
is a nitroimidazole antibiotic effective against anaerobes that is
routinely used in the treatment of inflammatory bowel diseases
(IBD) and has been shown to decrease postoperative recurrence in
Crohn’s disease (CD) patients [17], diseases linked to uncontrolled
immune responses to the intestinal microbiota. However, the
effectiveness of the use of metronidazole in the treatment of CD is
still under debate [18]. Some studies have shown a positive effect
of this drug on CD treatment [17,19,20], whereas others show no
significant difference between metronidazole treatment and the
placebo [21,22].
The two strains of mice used in our models, 129S1/SvImJ and
C57BL/6, are commonly used as resistant and susceptible typhoid
infection models, respectively [23,24]. One difference in these
mice is that C57BL/6 mice possess a point mutation in the gene
encoding Nramp1, leading to a non-functional protein. As a result,
these mice are susceptible to S. Typhimurium, and succumb to
uncontrolled bacterial replication [23]. 129S1/SvImJ, on the other
hand, express Nramp1 and are able to survive S. Typhimurium
Figure 5. Predisposition to colitis can be associated with
phylum-level changes in the composition of the intestinal
microbiota caused by antibiotic treatments. Fluorescent in situ
hybridization (FISH) of fecal samples of 129S1/SvImJ and C57BL/6 mice
before and after antibiotic treatment. Met: metronidazole (750 mg/ L)
and Strep: streptomycin (450 mg/ L). Black bars represent the
percentage of bacteria belonging to the BAC phyla. White bars
represent the percentage of bacteria belonging to the GAM phyla
and gray bars represent the percentage of Firmicutes and other groups.
Experiments were performed three times with at least 4 mice in each
group.
doi:10.1371/journal.pone.0020338.g005
Figure 6. MIB and Lactobacillus sp. levels are associated to
predisposition to S. Typhimurium-induced colitis. A. Levels of
MIB on fecal samples of 129S1/SvImJ and C57BL/6 mice before and after
antibiotic treatment, as determined by RT-PCR. B. Levels of Lactobacillus
on fecal samples of 129S1/SvImJ and C57BL/6 mice before and after
antibiotic treatment, as determined by RT-PCR. ns: not significant;
*: p,0.05; **: p,0.01; ***: p#0.001. Experiments were performed three
times with at least 4 mice in each group.
doi:10.1371/journal.pone.0020338.g006
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was the determining factor in the differences in susceptibility to
colitis upon metronidazole treatment displayed by these two
mouse strains. The intestinal pathology of infected 129S1/SvImJ
and an isogenic mutant of Nramp1 2/2 after metronidazole
treatment was analyzed and no differences were observed,
indicating that Nramp1 is not involved in this phenomenon.
Although one of the major differences between 129S1/SvImJ and
C57BL/6 mouse strains is Nramp1 expression, there are other
genetic differences with known impacts on inflammatory respons-
es, such as C5 deficiency and Vnn haplotype differences that may
be playing a role in these phenotypic differences [25,26,27,28]. We
hypothesize that differences in the intestinal microbiota between
these two models may be one of the important factors in
determining susceptibility to colitis.
In this work, we explored the intestinal microbiota composition
as a player in the development of S. Typhimurium-induced colitis
in mice. We demonstrated that significant differences in the
composition of the intestinal microbiota during antibiotic
treatment of the two different mouse strains are strongly associated
with predisposition to colitis. By comparing streptomycin versus
metronidazole treatment of 129S1/SvImJ and metronidazole
treatment of C57BL/6 versus 129S1/SvImJ, we were able to
circumvent issues related to host genetics and potential direct
effects of antibiotics on the host, thus substantiating the role of the
microbiota in infection. Our data suggests that specific members of
the microbiota are linked to protection against inflammation but
do not affect S. Typhimurium colonization. These members are
overrepresented when 129S1/SvImJ mice are treated with
metronidazole, but they decrease or are unchanged after
streptomycin treatment in these mice or metronidazole treatment
in C57BL/6 mice. Our data indicates that they belong to the
Bacteroidetes (BAC) phylum, particularly to the Porphyromona-
daceae family, which is represented here by Mouse Intestinal
Bacteria (MIB). MIB are part of a recently discovered operational
taxonomic unit (OTU), which is very closely related to Bacteroides.
It is present in all parts of the intestinal tract of mice [11] and is
also found in lower numbers in human feces [29]. In addition to
the increased numbers of MIB in mice resistant to S. Typhimur-
ium-induced colitis, we also found bacterial groups that seem
correlated with susceptibility to colitis. These include Lactobacillus
sp., which belong to the Firmicutes phylum and are present in the
intestinal tract of many animals [11]. Several studies have shown a
positive effect of different species of Lactobacillus on protecting
against intestinal pathophysiology [30]. However, most clinical
trials showed that these bacteria were not able to induce remission
in IBD patients [31,32,33]. Our data indicates that Lactobacillus sp.
levels are significantly increased in streptomycin-treated 129S1/
SvImJ and metronidazole-treated C57BL/6 mice, both predis-
posed to infectious colitis. In agreement with this finding, a recent
study revealed that certain prebiotics, which stimulate the growth
of Lactobacillus sp., among other bacteria, increase the severity of S.
Typhimurium infection in mice [34]. The increase of Lactobacillus
sp. occurred only in instance of reduced Bacteroidetes, and
therefore it is not possible to determine which one of these events is
responsible for the control of the inflammatory response to
Salmonella infection observed herein. Furthermore, the fact that
Lactobacillus sp. levels in control C57BL/6 mice (resistant to colitis)
are higher than in streptomycin-treated 129S1/SvImJ mice
(susceptible to colitis) (Figure 4C) indicates an indirect effect of
these species on susceptibility to colitis. Although a strong
correlation is shown here, further studies are necessary to prove
a definitive causal link between these bacteria and S. Typhimur-
ium-induced colitis.
Recently, it was shown that metronidazole alters the gut
microbiota of rats and reduces basal oxidative stress to proteins in
colonic tissue. It has also been demonstrated that this antibiotic
increases the thickness of the mucus layer and the presence of
Bifidobacteria, which would decrease intestinal inflammation in IBD
patients [12]. In our model, metronidazole treatment induces
protection against S. Typhimurium-induced intestinal inflamma-
tion only in one of the mouse strains tested. It is important to note
that treatment with this antibiotic did not increase the presence of
Bifidobacteria in these mice, suggesting that the potentially
protective role of Bifidobacteria in rats is distinct from the phenotype
observed in our study.
Our data strongly support the notion that specific microbial
components of the intestinal microbiota determine predisposition
to colitis. Since it has been known for several decades that the
intestinal microbiota protects against S. Typhimurium coloniza-
tion, it has been generally assumed that the protection against
colitis was a consequence of reduced levels of S. Typhimurium in
the intestines of untreated mice. However, our study adds another
layer of complexity to the role of the microbiota in protection
against infectious agents. We now know that the protection against
colonization and inflammation are two independent events, and
that different subsets of the microbiota are responsible for each
aspect of disease resistance. It has been know that certain
commensals produce molecules that can affect the host immune
system and protect against intestinal inflammation [35,36] and this
might be the case in our study. Dissecting the potentially
numerous unidentified roles of microbial members of the intestinal
biota will be fundamental in our quest towards understanding the
complexities of the human body and its relationship with our
microbe partners.
Materials and Methods
Ethics Statement
All animal experiments were performed in strict accordance
with the guidelines of the University of British Columbia Animal
Care Committee and the Canadian Council on the Use of
Laboratory Animals. The protocol was approved by the UBC
Animal Care Committee (Certificate number: A09-0168). The
mice were euthanized by CO2 asphyxiation and all efforts were
made to minimize suffering.
Mice
Female, age-matched (6–8 weeks old) C57BL/6 and 129Sv/ImJ
Nramp1 2/2 and Nramp1 +/+ [8,37] mice were obtained from
Jackson Laboratory (Bar Harbor, ME) or from a breeding colony
maintained at the Wesbrook Animal Unit at The University of
British Columbia. Nramp1 2/2 mice have a null allele at the
Nramp1 locus (the Nramp1 gene was interrupted by an inserted
neomycin cassette), and thus, mRNA transcripts are absent. Mice
were fed a standard sterile chow diet (Laboratory Rodent Diet
5001, Purina Mills, St. Louis, Missouri) ad libitum throughout the
experiments.
Bacterial Strains
Salmonella enterica serovar Typhimurium strain SL1344 [38] was
grown overnight at 37uC with shaking (200 rpm) in Luria-Bertani
(LB) broth. This strain is resistant to streptomycin, metronidazole
and vancomycin.
Antibiotic treatments and S. Typhimurium infection
Mice were treated with 450 mg/L of streptomycin (Sigma) or
50 mg/L vancomycin (Sigma) in drinking water for 2 days or
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Antibiotics were dissolved in filter-sterilized water; control mice
were given water without antibiotics. After the antibiotic treatment
period, regular drinking water was returned and mice were
infected with ,2.7610
8 S. Typhimurium in LB broth by oral
gavage. Uninfected control mice were given 100 mL of sterile LB
broth. At 4 days post-infection, mice were euthanized by CO2
asphyxiation and samples were harvested aseptically for further
analysis. Antibiotic-treated, uninfected mice were euthanized by
CO2 asphyxiation after the treatment period.
Sample collection and assessment of S. Typhimurium
colonization
Caeca, spleen and feces were collected in 1 mL of sterile
phosphate-buffered saline (PBS). The samples were kept on ice
and homogenized with an MM 301 Mixer Mill (Retsch, Newton,
PA). Serial dilutions of the homogenates were plated on LB agar
plates supplemented with 100 mg/mL of streptomycin to enumer-
ate S. Typhimurium. Plates were incubated overnight at 37uC and
colonies were counted after incubation. Fecal samples were also
collected throughout the experiments and kept at 280uC for
further microbiota analysis.
Histopathology
Caecal samples were collected and fixed in 10% neutral
buffered formalin overnight and then placed into 75% ethanol.
Fixed tissues were embedded in paraffin and cut into 5 mm
sections. Tissues were stained with hematoxylin and eosin (H&E)
using standard techniques by Wax-it Histology Services (Vancou-
ver, BC, Canada) and UBC Histology Laboratory. Pathological
scores were assigned as previously described [39]. Briefly, the
scoring system was performed as follows: for lumen, sum of empty
(score 0), necrotic cells (scant 1, moderate 2, dense 3) and PMNs
(scant 2, moderate 2, severe 3); for surface epithelium, sum of no
pathological change (score 0), regenerative changes (mild 1,
moderate 2, severe 3), desquamation (patchy 1, diffuse 2), PMNs
(score 1), ulceration (score 1); for mucosa, sum of no pathological
change (score 0), crypt abscesses (rare 1, moderate 2, abundant 3),
presence of mucinous plugs (score 1) and granulation tissue (score
1); for submucosa, sum of no pathological changes (score 0),
mononuclear cell infiltrate (one small aggregate 0, more than one
1, large aggregates plus increase single cells 1), PMN infiltrate
(single 1, aggregates 2) and edema (moderate 1, severe 2).
Pathology Images were taken using a Zeiss Axioskop 2
microscope.
Microbiota analysis
Total bacterial counts from fecal samples were performed using
SYBR Green staining as described previously [40]. Briefly, a 1:10
dilution of the homogenized fecal samples were fixed and stored in
3.7% formalin at 4uC. Two mL were stained with 0.25 mLo f
SYBR Green (Invitrogen) and viewed with an Olympus 1x81
microscope. Cells were counted from three randomly chosen fields
and the numbers averaged. Counts were corrected based on
volume used, dilution and the known diameter of the microscope
field. Fluorescent in situ hybridization (FISH) was performed as
previously described [7]. Five to 100 mL of sample was hybridized
to 250 ng of the general EUB338 probe (59-GCT GCC TCC
CGT AGG AGT-39), fluorescently labeled with Texas Red [41]
and 250 ng of either the CFB286 (59-TCC TCT CAG AAC CCC
TAC-39) or GAM42a (59-GCC TTC CCA CAT CGT TT-39)
probes [42] labeled with fluorescein, then viewed and counted as
described for SYBR staining. The percentage compositions of
Bacteroidetes and Gammaproteobacteria were calculated by
dividing the numbers obtained for each phylum by the total
number of Eubacteria. The remaining bacteria were defined as
Firmicutes and others, as previously described [7].
Enumeration of viable bacteria from the fecal microbiota
Fecal samples were collected in 1 mL of PBS with 0.5%
cysteine, homogenized with an MM 301 Mixer Mill and
immediately taken to an anaerobic chamber. Serial dilutions were
performed in PBS containing 0.5% cysteine and plated in
Tryptose blood agar base, Reinforced clostridial agar, Rogosa
and Anaerobe basal agar (Oxoid). Tryptose blood agar base and
Anaerobe basal agar were supplemented with 7% sheep blood
(Cedarlane). Plates were incubated under aerobic (Tryptose blood
agar base) or anaerobic conditions (all the media) for 48h at 37uC
and colonies were counted after incubation.
Terminal-Restriction Fragment Length Polymorphism
(TRFLP)
Total DNA was isolated from fecal and caecal samples using the
QIAamp DNA stool kit (Qiagen) according to the manufacturer’s
instructions with the addition of a bead-beating step. Polymerase
Chain Reaction (PCR) was performed to amplify bacterial 16S
rDNA present in fecal samples using broad-range bacterial
primers Bact8F(FAM) (59-AGA GTT TGA TCM TGG CTC
AG-39) [43] labeled with 6-carboxyfluorescein on the 59-end and
926R (59-CCG TCA ATT CCT TTR AGT TT-39) [44]. The
PCR products were digested with MspI (New England Biolabs,
Ipswich, MA) and sent to analysis at NAPS (Michael Smith
Laboratories, Vancouver, BC). Electropherograms were processed
using Gene Marker v.1.75 software (State College, PA) and
relative peak areas of terminal restriction fragments corresponding
to sizes between 50–600 bp were analyzed. Data were plotted
using PC-ORD5 software (MjM Software, Gleneden Beach, OR).
Cloning and Sequencing
Clone libraries were generated for the phylogenetic classifica-
tion of TRFs of interest. PCR amplified 16S rRNA genes from
DNA isolated from feces were cloned into the TA pCRH 4 TOPO
vector and inserted into Escherichia coli chemically competent cells
(Invitrogen). Transformants were screened by TRFLP as previ-
ously described, and those coinciding with peaks of interest were
sequenced. Sequences were classified using the naı ¨ve Bayesian
rRNA classifier in RDP [45].
Quantitative Real-Time PCR (RT-PCR)
The abundance of specific intestinal bacterial groups in DNA
extracted from fecal samples was measured by RT-PCR on a 7500
Fast Real-Time System (Applied Biosystems, Foster City, CA).
The reactions were performed using Quantitec SYBR Green
mastermix (Qiagen) with the following group-specific 16S rDNA
primers (IDT, Coralville, IA). Eubacteria (all bacteria): UniF340
ACT CCT ACG GGA GGC AGC AGT and UniR514 ATT
ACC GCG GCT GCT GGC (60uC) [46]; Mouse Intestinal
Bacteria (MIB): UNI516F CCA GCA GCC GCG GTA ATA and
ambMIBR677 CGG CAT TCC GCR TAC TTC TC (60uC)
([46] and this study); Lactobacillus/Lactococcus: LabF362 ACG AGT
AGG GAA ATC TTC CA and LabR677 CAC CGC TAC ACA
TGG AG (56uC) [46]; Segmented Filamentous Bacteria (SFB):
SFB736F GAC GCT GAG GCA TGA GAG CAT and SFB844R
GAC GGC ACG GAT TGT TAT TCA (58uC) [46]; Bifidobacter-
ium BIF164 GGG TGG TAA TGC CGG ATG and BIF662 CCA
CCG TTA CAC CGG GAA (62uC) [47]. Eubacteria primers
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total amount of bacteria in each sample. The RT-PCR program
started with two steps of 50uC for 2 minutes and 95uC for 10
minutes, followed by 40 cycles of 95uC for 30 seconds and 60uC
for 1 minute, when data was acquired. The same DNA sample was
amplified using the group-specific primers described above
observing their different annealing temperatures at the final step.
Group-specific bacterial numbers were determined as a percent-
age of the numbers obtained with the Eubacteria primers.
ELISAs
Caecum homogenates were centrifuged twice at 16,000 g, and
the supernatants were stored at 280uC. The levels of interleukin-8
(IL8), interleukin-6 (IL6), interferon gamma (IFNc), tumor necrosis
factor alpha (TNFa) (R&D System, Minneapolis, MN) and
interleukin-22 (IL22) (eBioscience, San Diego, CA) were measured
by enzyme–linked immunosorbent assays (ELISAs) according to
the manufacturers’ instructions.
Statistical Analysis
Statistical significance was calculated using the Mann-Whitney
test with a 95% confidence interval. All analyses were performed
using GraphPad Prism version 4.0 (GraphPad Software, San
Diego, CA). The results were expressed as mean values with
standard errors of the means. Microbial community composition
was plotted using non-metric multidimensional scaling (NMS)
ordination based on Sorensen distance measure, and significance
between treatments was tested using the multiple response
permutation procedure (MRPP) in PC-ORD5 software (Gleneden
Beach, OR).
Supporting Information
Figure S1 Nramp1 is not responsible for the differences
in intestinal pathology between 129S1/SvImJ and
C57BL/6 mice observed following metronidazole treat-
ment and infection. A. S. Typhimurium levels in the caeca of
Nramp1 +/+ and Nramp1 2/2 129S1/SvImJ mice after 4 days
of infection with or without antibiotic treatment. B. S. Typhimur-
ium levels in feces of Nramp1 +/+ and Nramp1 2/2 129S1/
SvImJ mice after 4 days of infection with or without antibiotic
treatment. C. H&E staining of caeca of Nramp1 +/+ and Nramp1
2/2 129S1/SvImJ mice. (a). infected Nramp1 +/+ 129S1/SvImJ
mice; (b). metronidazole-treated and infected Nramp1 +/+
129S1/SvImJ mice; (c). infected Nramp1 2/2 129S1/SvImJ
mice; (d). metronidazole-treated and infected Nramp1 2/2
129S1/SvImJ mice. D. Pathology scores of caeca of Nramp1 +/
+ and Nramp1 2/2 129S1/SvImJ mice after 4 days of infection
with or without antibiotic treatment. Met: metronidazole
(750 mg/L). Black bars represent pathology scores of the intestinal
lumen, white bars represent scores of the surface epithelia, dark
grey bars represent scores of the mucosa and light grey bars
represent scores of the submucosa of the tissue. ns: not significant;
*: p,0.05; **: p,0.01. Experiments were performed three times
with at least 4 mice in each group.
(EPS)
Figure S2 Determination of viable bacteria in fecal
samples incubated in aerobiosis and anaerobiosis in
Tryptose blood agar base. Total bacterial counts in control,
metronidazole-treated or streptomycin-treated uninfected 129S1/
SvImJ mice and control and metronidazole-treated uninfected
C57BL/6 mice. Aerobiosis (black bars) and Anaerobiosis (white
bars).
(EPS)
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